In PPGL, GLP-1RA or tirzepatide could be beneficial also considering the reduced GLP-1 production secondary to catecholamine hypersecretion
Peak results often occur around 612 months, depending on your starting weight, dose tolerance, and adherence to lifestyle changes
Semaglutide influences areas of the brain that control appetite and also slows down digestion, both of which lead to lower calorie consumption
When They Should Not Be First-Line Therapy Despite their efficacy, novel weight loss peptides should generally not replace GLP-1 or GIP receptor agonists as initial therapy for uncomplicated obesity
Approximately 37% of people admitted for semaglutide complications were admitted to the hospital
The transformation involves appetite regulation, metabolic function, cardiovascular risk markers, sleep quality, and energy levels